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Background: Hepatitis C virus (HCV) remains a worldwide health-care burden. Prevalence 
rates vary and the distribution of genotypes depends on geographical location. Here, the 
recent prevalence of HCV infections and distribution of HCV genotypes among Korean blood 
donors were studied.  
Methods: Between February 2005 and December 2009, a total of 11,064,532 donors were 
screened for anti-HCV and 11,412,690 donors were screened for HCV RNA. HCV genotyp-
ing was conducted for 748 blood donors with HCV RNA by using the line probe assay 
(VERSANT HCV Genotype 2.0 Assay, Bayer Healthcare, USA) after amplification of the 
5’-untranslated and core regions of the genome. 
Results: The anti-HCV prevalence was 0.16% (17,250/11,064,532). HCV RNA was detect-
ed in 959 out of the 11,412,690 donors (8.4/100,000). HCV RNA was more prevalent among 
women, donors who resided at harbor sites, and first-time donors. In addition, the preva-
lence of HCV RNA increased with age. The genotypes of 740 out of the 748 tested donors 
(98.9%) were identified. HCV genotype 1b (47.7%) and 2a/2c (35.0%) were dominant. 
Genotypes 2 (7.6%), 2b (2.3%), 3a (1.6%), 1a (1.3%), 1 (0.9%), 2v (0.5%), 1v (0.1%), and 
3 (0.1%) were also identified. Genotype 4a/4c/4d (0.1%) was detected for the first time in 
one Korean blood donor.
Conclusions: The distribution of HCV genotypes in Korea has not changed remarkably, with 
the exception of genotype 4a/4c/4d. A periodic study to monitor the prevalence of HCV in-
fections and the distribution of HCV genotypes is required to identify emerging genotypes in 
Korea.
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INTRODUCTION
Hepatitis C is a major public health problem in numerous coun-
tries [1]. Chronic hepatitis C is the third most common cause of 
chronic liver disease and hepatocellular carcinoma in Korea, fol-
lowing hepatitis B viral infections and alcohol-induced hepatitis 
[2]. Blood transfusions have been a leading cause of hepatitis C 
virus (HCV) transmission. Since 2005, blood donors in Korea 
have been tested not only for anti-HCV but also for HCV RNA, 
and an eligible donor selection strategy has been enforced. Since 
this enforcement, HCV transmission through transfusion has not 
yet been reported in the Korean population.
  The prevalence of anti-HCV antibodies among Koreans older 
than 40 yr was approximately 1.29% (95% confidence interval, 
1.12-1.48%) [3-7]. The latest reported prevalence of anti-HCV in 
Korean blood donors was 0.1% (Korean Red Cross (KRC), 2010, 
unpublished data). However, this rate may underestimate the 
actual prevalence of HCV infections in the general population 
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because donors are generally highly selected [8].
  The prevalence of HCV infections confirmed by HCV nucleic 
acid amplification testing (HCV NAT) was only approximately 
0.006% (KRC, 2010, unpublished data), which was much lower 
than the prevalence reported using anti-HCV testing.
  HCV is a single-stranded RNA virus of the Flaviviridae family 
[9]. HCV is divided into 6 genotypes and numerous sub-geno-
types [10]. Striking nucleotide sequence diversity has been re-
ported for HCVs isolated from different geographical areas [11, 
12]. The genotypes can have up to 30% nucleotide sequence 
difference [10, 13]. Different genotypes may respond differently 
to antiviral treatment [14]. 
  HCV genotypes 1 and 2 (sub-genotype 1b and 2a) are the 
most dominant genotypes in Korean patients and health exam-
inees [2, 3, 15-21]. Most Korean studies have been performed 
using small number of samples from a selected population. The 
purpose of this study was to determine the recent prevalence of 
HCV infections and the distribution of HCV genotypes among a 
large number of Korean blood donors. 
METHODS
1. Materials
The study was conducted at the KRC Central Blood Laboratory 
Center, Seoul. A total of 11,064,532 blood donors were tested for 
anti-HCV antibodies. HCV NAT was conducted for 11,412,690 
donors (including hospital blood centers) between February 
2005 and December 2009. Samples with reactive results in the 
HCV NAT were collected from 3 KRC laboratories (Central, Jung-
Bu, Nam-Bu) and stored at -80°C. Of the 959 samples with 
plasma HCV RNA, only 748 samples could be genotyped in this 
study (for various reasons). With approval from the KRC Institu-
tional Review Board (4th, 2010), demographics of the HCV in-
fected donors at the KRC (959 HCV RNA reactive donors), in-
cluding gender, age, and residence site, were reviewed through 
the Blood Information Management System (BIMS) of the KRC.
2. Serologic screening tests
All samples were tested for anti-HCV antibodies using the third 
generation enzyme immunoassay (LG HCD 3.0 TMB, LG Chem-
ical Ltd., Seoul, Korea). Positive hits using this immunoassay 
were confirmed using the recombinant immunoblot assay (RIBA) 
(LG HCD confirm, LG Chemical Ltd.).
3. HCV NAT
Two HCV NAT formats were used: Procleix HIV-1/HCV enhanced 
Semi-Automation System (eSAS, Novartis/Gen Probe, Emeryville, 
CA, USA) and Ampliscreen bioMerieux combination system us-
ing COBAS AmpliScreen HCV Test (Roche Diagnostics, Branch-
burg, NJ, USA) and NucliSens EasyMag (bioMerieux, Boxtel, 
The Netherlands).
4. HCV genotyping using the line probe assay
HCV-RNA was extracted from 200 μL of plasma using the QIAamp 
MinElute Virus Spin Kit (Qiagen, Hilden, Germany) following the 
manufacturer’s instructions. cDNA was synthesized immedi-
ately after RNA extraction. Reverse transcription PCR (RT-PCR) 
was conducted using the VERSANT HCV Amplification 2.0 Kit 
(Bayer Healthcare, Tarrytown, NY, USA) and performed using a 
PTC-100 Thermal Cycler (MJ Research, Waltham, MA, USA). 
Reverse hybridization (using line probe assay [LiPA] for geno-
typing of HCV) was performed using the VERSANT HCV Geno-
type 2.0 assay (INNO-LiPA HCV 2.0, Bayer Healthcare). Before 
probe hybridization, we evaluated the degree of gene expression 
using agarose gel electrophoresis of the PCR products (2% aga-
rose, SeaKem LE, Cambrex, Rockland, ME, USA) by comparing 
the PCR product band with a 100-bp DNA ladder (Promega, 
Madison, WI, USA). The genotypes (and sub-genotypes) of HCV 
were identified by comparing the expressed genes on assay 
strips to a Reading Card, and the results were interpreted ac-
cording to the guidelines of the manufacturer. The genotypes 
and sub-genotypes, which can be discriminated by VERSANT 
HCV Genotype 2.0 assay kit are 1, 1a, 1b, 1a/1b, 2, 2a/2c, 2b, 3, 
3a, 3b, 3c, 3k, 4, 4a/4c/4d, 4b, 4e, 4f, 4h, 5a, and 6a/6b. 
5. ALT assay
The ALT assay was performed using the kinetic method (SICDIA 
L ALT reagent, Shin Yang Pharm., Seoul, Korea). The proportion 
of individuals showing abnormal ALT activities (>65 IU/L) were 
compared between the 959 HCV NAT reactive donors and non-
reactive donors.
6. Statistical analysis
The chi-square test was used to analyze the significance of the 
difference between 2 groups; P values <0.05 were considered 
significant.
RESULTS
1.     Prevalence of anti-HCV and HCV RNA among Korean 
blood donors
The Anti-HCV repeated reactive rate for blood donors was 0.16% Oh DJ, et al.
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(17,250/11,064,532), and HCV RNA was detected in 959 out of 
the 11,412,690 (8.4/100,000) blood donors (Table 1). Eighteen of 
these 959 donors donated blood during the window period. The 
prevalence (number/100,000) of HCV-infected blood donations 
decreased from 11.7 in 2005 to 6.2 in 2009 (Table 2). Of the HCV 
NAT reactive donors, 98.7% (881/893) were also RIBA positive.
2.     Demographics of HCV RNA reactive Korean blood donors
1) Gender and age
The prevalence of HCV RNA was higher in females than males 
(10.16/100,000 vs. 7.85/100,000; P=0.0003) and increased with 
age (P=0.0011) (Table 3). 
2) Residence site and donation time
The prevalence of HCV RNA was higher in donors residing near 
harbor sites such as Busan and Incheon than in those residing 
at other sites (15.7/100,000 vs. 7.2/100,000; P<0.0001) (Table 
4). First-time blood donors were more likely to test positive for 
HCV RNA than repeat donors (31.3/100,000 vs. 1.3/100,000; P< 
0.0001). 
3.     Frequency of abnormal ALT activities in HCV RNA reactive 
KRC blood donors
The proportion of individuals showing ALT abnormalities (≥65 
Table 4. Prevalence of HCV RNA among Korean blood donors by 
residence sites
Residence site Donors HCV NAT 
reactive
Prevalence
(/100,000)
P value
Harbor site 1,629,297 255 15.7
Other sites 9,783,393 704 7.2 <0.0001
Total 11,412,690* 959 8.4
*Donors at the KRC and hospital blood centers.
Abbreviations: HCV, hepatitis C virus; NAT, nucleic acid amplification test-
ing; KRC, Korean Red Cross.
Table 1. Prevalence of anti-HCV and HCV RNA among Korean blood 
donors
Anti-HCV (%) HCV NAT (%)
Donors* Reactive Nonreactive Donors
† Reactive Nonreactive
11,064,532 17,250 11,047,282 11,412,690 959 11,411,731
(100.00) (0.16) (99.84) (100.00) (0.0084) (99.9916)
*Donors at the KRC; 
†Donors at the KRC and hospital blood centers.
Abbreviations: HCV, hepatitis C virus; NAT, nucleic acid amplification test-
ing; KRC, Korean Red Cross.
Table 2. Prevalence of HCV RNA among Korean blood donors*
Year Donors HCV NAT (%) Prevalence (/100,000)
2005
† 2,105,248 246 (0.012) 11.7
2006 2,302,542 229 (0.010) 9.9
2007 2,087,762 169 (0.008) 8.1
2008 2,347,184 156 (0.007) 6.6
2009 2,569,954 159 (0.006) 6.2
Total 11,412,690* 959 (0.008) 8.4
*Donors at the KRC and hospital blood centers; 
†No data was available for 
January.
Abbreviations: HCV, hepatitis C virus; NAT, nucleic acid amplification test-
ing; KRC, Korean Red Cross.
Table 3. Prevalence of HCV RNA among Korean blood donors cat-
egorized by age and gender
Age Donors HCV NAT reactive
Number (/100,000)
HCV NAT reactive
Male Female
10s 3,915,778 35 (0.9) 24 (1.0) 11 (0.8)
20s 5,324,973 165 (3.1) 95 (2.2) 70 (6.8)
30s 1,433,200 304 (21.2) 233 (18.7) 71 (37.4)
40s 564,223 316 (56.0) 230 (48.0) 86 (100.6)
50s 160,923 116 (72.1) 85 (60.9) 31 (144.9)
>60 13,593 23 (169.2) 16 (131.4) 7 (495.4)
11,412,690* 959 (8.4) 683 (7.85) 276 (10.16)
*Total number of donors at the KRC and hospital blood centers.
Abbreviations: HCV, hepatitis C virus; NAT, nucleic acid amplification test-
ing; KRC, Korean Red Cross.
Table 5. Distribution of HCV genotypes among Korean blood donors
Genotype Sub-genotype  HCV NAT reactive donors (%)
1 1   7 (0.9)
1a 10 (1.3)
1b 357 (47.7)
1v  1 (0.1)
1 subtotal 375 (50.1)
2 2a/2c 262 (35.0)
2b 17 (2.3)
2 57 (7.6)
2v 4 (0.5)
2 subtotal 340 (45.5)
3 3  1 (0.1)
3a 12 (1.6)
3 subtotal 13 (1.7)
4 4a/4c/4d 1 (0.1)
Mixed 11 (1.5)
No Amp*    2 (0.3)
Undetermined
†    6 (0.8)
Total 748 (100.0)
*Nucleic acid was not amplified; 
†Not available for genotyping. 
Abbreviations: HCV, hepatitis C virus; NAT, nucleic acid amplification testing.Oh DJ, et al.
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IU/L) was higher in HCV RNA reactive donors than in the con-
trol group (30.2% vs. 1.6%).
4. Distribution of HCV genotypes
HCV genotypes were determined for 740 of the 748 blood donors 
(98.9%) (Table 5). The dominant HCV genotypes of Korean blood 
donors were 1b (357/748, 47.7%) and 2a/2c (262/748, 35.0%); 
genotype 1 (7/748), 1b, 1a (10/748), and 1v (1/748) constituted 
50.1% of the blood donors (375/748); genotype 2 (57/748), 2a/2c, 
2b (17/748), and 2v (4/748) constituted 45.5% (340/748). Geno-
type 3 (1/748) and 3a (12/748) were also observed. Genotype 
4a/4c/4d (1/748) was identified in one donor. Eleven donors were 
co-infected with different subtypes, e.g., 1b+2a/2c (3/748), 1b+1a 
(2/748), 1b+2 (2/748), 1b+3 (1/748), and 1b+2a/2c+3a (1/748). 
  The gender, age, and residence site of the donors were not 
significantly different in donors infected with HCV genotypes 1b 
and 2a/2c: P=0.106 (gender); P=0.961 (age); P=0.931 (resi-
dence site) (Table 6). 
DISCUSSION
Infections in 18 donors, who donated during the window period 
from 2005 to 2009 could be detected by HCV NAT. The preva-
lence of anti-HCV (0.16%) and HCV RNA (8.4/100,000) in blood 
donors did not appear to reflect the true prevalence of HCV in-
fections in the Korean population. According to monthly reports 
in 2011 (KRC, 2011; unpublished data), the anti-HCV prevalence 
in a military recruit training center was 0.29%, which was higher 
than that observed for blood donors (0.16%).
  Anti-HCV repeated reactive donors were confirmed by using 
RIBA supplementary test and HCV NAT screening. Only 5-10% 
of the anti-HCV repeated reactive donors were estimated to be 
RIBA positive, and 60-70% of the RIBA-positive donors con-
tained HCV RNA. The true prevalence of HCV infections is thus 
better defined as the prevalence of HCV NAT-reactive donors. 
The true prevalence of HCV infections among Korean donors, 
confirmed by RIBA and HCV NAT is approximately 0.006% 
(KRC, 2010; unpublished data), which is much lower than the 
prevalence of anti-HCV.
  We evaluated demographics such as the gender, age, resi-
dence site, and donation time of the HCV RNA reactive donors 
at the KRC. We only used donor information provided by the 
BIMS and did not perform any epidemiologic studies. Elderly do-
nors showed a higher frequency of HCV infection compared with 
young donors. Exposure to acupuncture has been reported as a 
significant risk factor for the elderly in rural areas [2]. The reason 
for the high frequency of HCV RNA in females is unclear. The 
high frequency of HCV RNA in donors who lived around harbor 
sites appeared to be associated with environmental factors.
  KRC has implemented a healthy donor registry program since 
2000 and the program is important for decreasing the prevalence 
of HCV infections of donors.
  HCV is single-stranded RNA virus of approximately 9.4 kb; its 
gene structure was identified in 1989 by Choo et al. [9, 22]. The 
classification of HCV into 6 genotypes and approximately 80 
sub-genotypes (proposed by Simmonds et al.) is widely used 
and is based on the nucleotide sequence of NS5 [10]. Methods 
for HCV genotyping include direct analysis of nucleotide se-
quences, LiPA, restriction fragment length polymorphism, and 
restriction fragment mass polymorphism. We used LiPA, a ge-
notyping kit, which is technically simple, cost-effective, and sim-
plifies the interpretation of most HCV genotypes. However, LiPA 
cannot distinguish between genotype 1b and 1a, between 2c 
and 2a, and between 4a, 4c, and 4d because of the high homo-
geneity in the 5’-untranslated regions (UTRs) of different sub-
types. Recently, the performance of LiPA reagents for 5’-UTRs 
was improved by simultaneous amplification of the genomic 
core region. Thus, the reagents have been upgraded in accor-
dance with the newly classified nomenclature (developed in 
2005), thereby mitigating this weakness to some extent [23].
  HCV genotypes 1, 2, and 3 are distributed throughout the 
world. Genotype 4 is mainly found in the Middle East and Africa, 
Table 6. Distribution of HCV genotype according to the gender, age and residence site
Genotype
Gender Age Residence site
Total (%)
Male Female 10s 20s 30s 40s 50s >60 Harbor site Other sites
1b (%) 256 (48.2) 101 (46.5) 12 (48.0) 67 (51.1) 108 (44.4) 121 (51.9) 43 (43.8) 6 (33.3) 111 (50.9) 246 (46.4) 357 (47.7)
2a/2c (%) 191 (35.9) 71 (32.7) 4 (16.0) 40 (30.5) 90 (37.0) 81 (34.9) 38 (38.7) 9 (50.0) 69 (31.6) 193 (36.4) 262 (35.0)
Others (%) 84 (15.8) 45 (20.7) 9 (36.0) 24 (18.3) 45 (18.5) 31 (13.3) 17 (17.3) 3 (16.7) 38 (17.4) 91 (17.1) 129 (17.2)
Total (%) 531 (71.0)  217 (29.0) 25 (3.3) 131 (17.5) 243 (32.5) 233 (31.1) 98 (13.1) 18 (2.4) 218 (29.1) 530 (70.9) 748 (100.0)
Abbreviation: HCV, hepatitis C virus.Oh DJ, et al.
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and it has recently been identified among European immigrants 
that moved from Africa or the Middle East; this indicates that 
the distribution of these viral genotypes is changing because of 
population redistribution. Genotypes 5 and 6 are found in south-
ern Africa and in Asia, respectively. Genotypes 1b and 2 are 
dominant in Japan and Taiwan. Genotype 6 is commonly found 
in Hong Kong, Vietnam, and Laos [1, 12, 24-26]. HCV genotypes 
1b and 2a are dominant in Korea. The distribution of HCV geno-
types in this study confirmed the results reported previously [2, 
3, 15-19]. Although the test kit did not discriminate between 2a 
and 2c, HCV genotypes 1b (47.7%) and 2a/2c (35.0%) were 
dominant. Various genotypes such as 1, 1a, 2b, 2, and 2v were 
also identified. The frequency of genotypes 3 and 3a is still low 
among Korean blood donors. However, identification of the 4a/ 
4c/4d genotype in one blood donor is intriguing. This donor was 
a 40-yr-old male with moderately elevated ALT activity (57 IU/L) 
and with a viral load of 1.2×10
6 IU/mL. An epidemiological 
study for investigating the route of HCV infection could not be 
performed. This case may be the first HCV infection with a 4a/ 
4c/4d genotype in Korean blood donors. Genotype 3 is the dom-
inant genotype among young people; in comparison, genotypes 
1 or 2 predominate in USA [27]. Genotypes 1b and 2a/2c are 
predominant in the elderly [25]. However, other researchers 
have reported that the age of the donors does not affect the 
HCV frequency [26]. In this study, genotypes 1b and 2a/2c are 
less frequent in teenagers compared with the elderly (64.0% vs. 
81.5-86.7%); however, this difference is not statistically signifi-
cant. Fortunately, dominant HCV genotypes among Koreans, in-
cluding genotypes 1 and 2, respond well to antiviral therapy [2].
  In conclusion, periodic studies to determine the prevalence of 
HCV infections and HCV genotypes in blood donors should be 
performed to monitor the emergence of new genotypes such as 
genotype 4a/4c/4d found in this study.
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